Proteostasis Therapeutics Inc (NASDAQ:PTI) insider Meenu Chhabra acquired 40,000 shares of the firm’s stock in a transaction that occurred on Monday, December 18th. The shares were purchased at an average price of $5.00 per share, with a total value of $200,000.00. Following the completion of the acquisition, the insider now owns 50,218 shares of the company’s stock, valued at approximately $251,090. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Proteostasis Therapeutics Inc (NASDAQ:PTI) traded up $0.55 during mid-day trading on Wednesday, reaching $5.02. The company’s stock had a trading volume of 2,282,900 shares, compared to its average volume of 366,847. Proteostasis Therapeutics Inc has a 12-month low of $1.41 and a 12-month high of $16.67.

Proteostasis Therapeutics (NASDAQ:PTI) last posted its quarterly earnings results on Tuesday, November 14th. The company reported ($0.56) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($0.72) by $0.16. The firm had revenue of $1.55 million during the quarter, compared to the consensus estimate of $1.38 million. Proteostasis Therapeutics had a negative return on equity of 93.15% and a negative net margin of 712.49%. equities research analysts predict that Proteostasis Therapeutics Inc will post -2.47 EPS for the current year.

A number of hedge funds have recently bought and sold shares of the business. LMR Partners LLP acquired a new stake in shares of Proteostasis Therapeutics in the second quarter valued at approximately $127,000. Jennison Associates LLC lifted its position in shares of Proteostasis Therapeutics by 6.2% in the second quarter. Jennison Associates LLC now owns 2,075,439 shares of the company’s stock valued at $9,713,000 after buying an additional 120,575 shares during the last quarter. FMR LLC lifted its position in shares of Proteostasis Therapeutics by 2.3% in the second quarter. FMR LLC now owns 2,944,915 shares of the company’s stock valued at $13,782,000 after buying an additional 66,111 shares during the last quarter. Dimensional Fund Advisors LP acquired a new stake in shares of Proteostasis Therapeutics in the second quarter valued at approximately $296,000. Finally, Bain Capital Public Equity Management LLC acquired a new stake in shares of Proteostasis Therapeutics in the second quarter valued at approximately $1,233,000. Hedge funds and other institutional investors own 68.03% of the company’s stock.

PTI has been the subject of a number of analyst reports. HC Wainwright restated a “buy” rating and issued a $15.00 price target on shares of Proteostasis Therapeutics in a research note on Tuesday. Zacks Investment Research downgraded Proteostasis Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, November 18th. Leerink Swann raised their price target on Proteostasis Therapeutics from $6.00 to $8.00 in a research note on Tuesday, December 12th. Finally, Robert W. Baird raised their price target on Proteostasis Therapeutics from $13.00 to $25.00 and gave the company an “outperform” rating in a research note on Tuesday, December 12th.

ILLEGAL ACTIVITY NOTICE: This piece of content was originally reported by Watch List News and is the sole property of of Watch List News. If you are accessing this piece of content on another site, it was illegally stolen and republished in violation of U.S. and international trademark and copyright laws. The legal version of this piece of content can be viewed at https://www.watchlistnews.com/proteostasis-therapeutics-inc-pti-insider-meenu-chhabra-purchases-40000-shares-of-stock/1774754.html.

About Proteostasis Therapeutics

Proteostasis Therapeutics, Inc is a biopharmaceutical company. The Company is engaged in discovery and development of therapeutics that treat diseases caused by an imbalance in the proteostasis network, a set of pathways that control protein biosynthesis, folding, trafficking and clearance. It has developed the Disease Relevant Translation (DRT) technology platform, a drug screening approach for identifying highly translatable therapeutics based on predictive and functionally pertinent phenotypic assays and disease relevant models.

Insider Buying and Selling by Quarter for Proteostasis Therapeutics (NASDAQ:PTI)

Receive News & Ratings for Proteostasis Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Proteostasis Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.